Tigecycline Patent Status
Tigecycline, sold as Tygacil by Pfizer, faces limited generic competition due to ongoing patent protections and regulatory hurdles. The primary composition-of-matter patent (US 7,485,741) expired in 2021, but key method-of-use and formulation patents extend exclusivity.[1] DrugPatentWatch lists 12 Orange Book patents for Tygacil, with the latest expiring in 2031 (US 8,410,076 for specific IV formulations).[1]
When Do Patents Expire?
- Core product patent: Expired June 2021.
- Key remaining patents:
- US 7,858,667 (methods of treatment): Expires 2025.
- US 8,410,076 (stable formulations): Expires June 2031.
- Pediatric exclusivity adds 6 months to some, pushing to late 2031.[1]
No generics launched post-2021 expiry due to secondary patents blocking ANDA approvals via Paragraph IV challenges.
Generic Entry Barriers
Generics require FDA approval under Hatch-Waxman, but Pfizer's patent thicket triggers 30-month stays on ANDA filings challenging listed patents. No Paragraph IV certifications filed yet per FDA records, delaying first generic until at least 2025 (earliest non-infringing expiry).[1][2] QIDP designation grants 5 extra years of exclusivity (ended 2020), compounding delays.
Are Companies Challenging Patents?
No active ANDA litigations reported. Pfizer defends aggressively; past suits (e.g., vs. generic filers pre-2021) settled with delayed entries. Potential challengers like Mylan or Teva could file Paragraph IV notices, risking suits but gaining 180-day exclusivity if successful.[1][3]
Impact on Pricing and Market
Tygacil lists at $1,800-$2,200 per 50mg vial (wholesale), with generics potentially cutting costs 80-90% post-entry.[4] Limited competition sustains high prices for hospitals treating resistant infections (e.g., MRSA, Acinetobacter). Biosimilar pathways don't apply as it's a small-molecule antibiotic.
Alternatives During Patent Life
Clinicians use IV ertapenem, meropenem, or colistin for similar multidrug-resistant infections, though tigecycline's glycylcycline structure offers unique broad-spectrum coverage.[5] No direct generics abroad affect US market due to import restrictions.
Sources
[1]: DrugPatentWatch.com - Tygacil Patents
[2]: FDA Orange Book - Tygacil
[3]: FDA Paragraph IV Database
[4]: Red Book Pricing Data
[5]: Clinical Guidelines - IDSA